Compare Abeona Therapeutics Inc (ABEO) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Jumia Technologies AG - ADR — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Jumia Technologies AG - ADR trades at $6.74 (market cap $859.54M). The key difference: Jumia Technologies AG - ADR is far larger — about 2.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | JMIA | |
|---|---|---|
Market Cap | $373.32M | $859.54M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $14.60 |
52-Week Low | $4.17 | $4.24 |
Enterprise Value | $228.22M | $806.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JMIA trades at $6.94, down 1.56% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 39% year-over-year, narrowing its adjusted EBITDA loss by 32%. Analyst consensus is strongly bullish with 71% buy ratings, supported by management's reaffirmed path to profitability by 2027. Cash flow improved in 2025 with a net inflow of $21.31 million, though the company remains unprofitable with a net income margin of -30.79%.
The outlook hinges on JMIA's execution toward its 2027 profitability target, with upside from African e-commerce expansion and partnerships like Starlink. Key risks include persistent losses, competitive pressures, and macroeconomic volatility in operating regions. Investors should weigh the growth potential against the high valuation multiples and financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
